CADL.US Candel Therapeutics Inc

Healthcare Biotechnology USA Stocks
6.20 USD
Close of Nov 14, 2026
4.35 14.00
Market cap
USD 474M
P/E
-
P/B
5.10x
ROE
-70.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CADL.US undervalued?

Graham number

The Graham number of Candel Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Candel Therapeutics Inc fundamental analysis

No fundamental analysis for Candel Therapeutics Inc yet.

Candel Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Candel Therapeutics Inc

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Pl…

Full company profile